Immunovia Future Growth
Future criteria checks 5/6
Immunovia is forecast to grow earnings and revenue by 76.7% and 152.1% per annum respectively while EPS is expected to grow by 76.5% per annum.
Key information
76.7%
Earnings growth rate
76.5%
EPS growth rate
Medical Equipment earnings growth | 22.1% |
Revenue growth rate | 152.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 622 | 173 | 143 | 146 | 1 |
12/31/2023 | 69 | -198 | -185 | -182 | 1 |
12/31/2022 | 1 | -152 | -128 | -127 | 1 |
9/30/2022 | 1 | -148 | -177 | -174 | N/A |
6/30/2022 | 1 | -161 | -180 | -175 | N/A |
3/31/2022 | 1 | -177 | -181 | -169 | N/A |
12/31/2021 | 1 | -156 | -177 | -153 | N/A |
9/30/2021 | 1 | -155 | -173 | -138 | N/A |
6/30/2021 | 0 | -157 | -176 | -133 | N/A |
3/31/2021 | 0 | -142 | -171 | -123 | N/A |
12/31/2020 | 0 | -146 | -168 | -121 | N/A |
9/30/2020 | 0 | -133 | -154 | -108 | N/A |
6/30/2020 | 0 | -120 | -150 | -106 | N/A |
3/31/2020 | 0 | -116 | -143 | -105 | N/A |
12/31/2019 | 0 | -115 | -129 | -92 | N/A |
9/30/2019 | -19 | -108 | -128 | -95 | N/A |
6/30/2019 | -13 | -99 | -122 | -89 | N/A |
3/31/2019 | -6 | -96 | -121 | -83 | N/A |
12/31/2018 | 0 | -87 | -121 | -84 | N/A |
9/30/2018 | 29 | -76 | -117 | -75 | N/A |
6/30/2018 | 26 | -70 | -102 | -63 | N/A |
3/31/2018 | 25 | -55 | -90 | -55 | N/A |
12/31/2017 | 24 | -45 | -78 | -46 | N/A |
9/30/2017 | 23 | -35 | -65 | -36 | N/A |
6/30/2017 | 24 | -28 | -57 | -25 | N/A |
3/31/2017 | 25 | -20 | -47 | -11 | N/A |
12/31/2016 | 24 | -15 | -43 | -12 | N/A |
9/30/2016 | 22 | -11 | -36 | -8 | N/A |
6/30/2016 | 22 | -9 | N/A | -8 | N/A |
3/31/2016 | 19 | -8 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMMNOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: IMMNOS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMMNOS is expected to become profitable in the next 3 years.
Revenue vs Market: IMMNOS's revenue (152.1% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: IMMNOS's revenue (152.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMMNOS's Return on Equity is forecast to be high in 3 years time